These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30137336)

  • 41. Persistence of HIV-1 resistance in lymph node mononuclear cell RNA despite effective HAART.
    Lafeuillade A; Khiri H; Chadapaud S; Hittinger G; Halfon P
    AIDS; 2001 Oct; 15(15):1965-9. PubMed ID: 11600824
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
    De Luca A; Sidumo ZJ; Zanelli G; Magid NA; Luhanga R; Brambilla D; Liotta G; Mancinelli S; Marazzi MC; Palombi L; Ceffa S
    BMC Infect Dis; 2017 Sep; 17(1):605. PubMed ID: 28870148
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antiretroviral resistance in individuals presenting therapeutic failure and subtypes of the human immunodeficiency virus type 1 in the Northeast Region of Brazil.
    Cavalcanti AM; Lacerda HR; Brito AM; Pereira S; Medeiros D; Oliveira S
    Mem Inst Oswaldo Cruz; 2007 Nov; 102(7):785-92. PubMed ID: 17992369
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of HIV genotypic drug resistance testing on the management and clinical course of HIV-infected children and adolescents.
    Dehority W; Deville JG; Lujan-Zilbermann J; Spector SA; Viani RM
    Int J STD AIDS; 2013 Jul; 24(7):549-53. PubMed ID: 23970770
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management.
    Bon I; Alessandrini F; Borderi M; Gorini R; Re MC
    New Microbiol; 2007 Jul; 30(3):313-7. PubMed ID: 17802917
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters.
    Pellegrin I; Thiébaut R; Blanco P; Viallard JF; Schrive MH; Merel P; Chêne G; Fleury H; Moreau JF; Pellegrin JL
    J Med Virol; 2005 Oct; 77(2):164-72. PubMed ID: 16121362
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy.
    Carr JM; Cheney KM; Coolen C; Davis A; Shaw D; Ferguson W; Chang G; Higgins G; Burrell C; Li P
    J Clin Microbiol; 2007 Apr; 45(4):1288-97. PubMed ID: 17314225
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy.
    Newman H; Breunig L; van Zyl G; Stich A; Preiser W
    J Clin Virol; 2014 Aug; 60(4):387-91. PubMed ID: 24929754
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
    Silver N; Paynter M; McAllister G; Atchley M; Sayir C; Short J; Winner D; Alouani DJ; Sharkey FH; Bergefall K; Templeton K; Carrington D; Quiñones-Mateu ME
    AIDS Res Ther; 2018 Nov; 15(1):18. PubMed ID: 30409215
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Presence of drug resistance mutations among drug-naive patients in Morocco.
    Annaz HE; Recordon-Pinson P; Baba N; Sedrati O; Mrani S; Fleury H
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):917-20. PubMed ID: 21087198
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
    Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
    Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy.
    Venturi G; Romano L; Carli T; Corsi P; Pippi L; Valensin PE; Zazzi M
    Antivir Ther; 2002 Dec; 7(4):245-50. PubMed ID: 12553478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative--Uganda.
    Weidle PJ; Downing R; Sozi C; Mwebaze R; Rukundo G; Malamba S; Respess R; Hertogs K; Larder B; Ochola D; Mermin J; Samb B; Lackritz E
    AIDS; 2003 Jul; 17 Suppl 3():S39-48. PubMed ID: 14565608
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China.
    Wang J; Wang Z; Liu J; Yue Y; Yang S; Huang H; He C; Liao L; Xing H; Ruan Y; Shao Y
    Sci Rep; 2015 Oct; 5():14823. PubMed ID: 26445885
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment.
    Armenia D; Zaccarelli M; Borghi V; Gennari W; Di Carlo D; Giannetti A; Forbici F; Bertoli A; Gori C; Fabeni L; Pinnetti C; Marocco R; Latini A; Ceccherini-Silberstein F; Mastroianni CM; Mussini C; Antinori A; Perno CF; Santoro MM
    J Clin Virol; 2018 Jul; 104():61-64. PubMed ID: 29738896
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Consistency of drug-resistant mutations in plasma and peripheral blood mononuclear cells of patients with treatment-naïve and treatment-experienced HIV-1 infection.
    Ma J; Chen Z; Fu C; Wei S; Liu J; Yang X; Chen X; Zhao Q; Sun Y; Huo Y
    Front Cell Infect Microbiol; 2023; 13():1249837. PubMed ID: 38179423
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and virological response to antiretroviral drugs among HIV patients on first-line treatment in Dar-es-Salaam, Tanzania.
    Mosha F; Ledwaba J; Ndugulile F; Ng'ang'a Z; Nsubuga P; Morris L; Kasubi M; Swai A; Vercauteren J; Vandamme AM
    J Infect Dev Ctries; 2014 Jul; 8(7):845-52. PubMed ID: 25022294
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The importance of testing genotypic resistance in proviral DNA of patients fully responding to highly active antiretroviral therapy.
    Palmisano L; Galluzzo CM; Giuliano M
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):233-4. PubMed ID: 19465827
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.